Pfizer’s prostate cancer combination delivers strong rPFS signal in TALAPRO-3
Talzenna plus Xtandi improved rPFS in HRR-mutated metastatic prostate cancer. Find out what TALAPRO-3 could change next.
Pharma & Biotech
Pharma & Biotech
What Johnson & Johnson’s AKEEGA opinion means for PARP inhibitors beyond castration resistance
Find out how Johnson & Johnson’s CHMP opinion for AKEEGA could shift prostate cancer treatment toward earlier, biomarker-guided precision therapy.
Pharma & Biotech
Gilead Sciences acquires RP-3467 from Repare Therapeutics in $30m synthetic lethality deal
Gilead Sciences acquires Repare’s RP-3467 Polθ inhibitor for up to $30M. Find out what this means for BRCA-targeted therapy and synthetic lethality M&A.
Features & Analysis
Is BRCA the new EGFR? Why germline mutations are reshaping prostate cancer treatment strategies
The recent FDA approval of Rubraca (rucaparib) for pre-chemotherapy use in BRCA-mutated metastatic castration-resistant prostate cancer marks a strategic inflection for the field. This expanded indication, driven by head-to-head superiority over docetaxel in the TRITON3 Phase 3 trial, positions BRCA mutations as the first molecular biomarker in prostate cancer to carry actionable, label-defining weight in
Pharma & Biotech
Is BRCA the new EGFR? Why germline mutations are reshaping prostate cancer treatment strategies
Rubraca’s FDA approval before chemo in BRCA-mutated prostate cancer could reshape precision treatment. See what this changes for mCRPC strategy.